Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
To assess anatomical and functional outcomes after switching from dexamethasone implant (DEXi) to fluocinolone acetonide implant (FAci) in 113 diabetic macular edema eyes, a multicentric retrospective observational study was conducted. Seventy-five eyes (73.5%) were switched 1–8 weeks after their la...
Main Authors: | Stéphanie Baillif, Pascal Staccini, Michel Weber, Marie-Noëlle Delyfer, Yannick Le Mer, Vincent Gualino, Laurence Collot, Pierre-Yves Merite, Catherine Creuzot-Garcher, Laurent Kodjikian, Pascale Massin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/14/11/2391 |
Similar Items
-
Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis
by: Jong G. Park, et al.
Published: (2020-09-01) -
Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study
by: Massin P, et al.
Published: (2016-07-01) -
Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
by: Coelho J, et al.
Published: (2019-09-01) -
Scleral fixation of fluocinolone acetonide implant
by: Homayoun Tabandeh, et al.
Published: (2020-09-01) -
Efficacy and Safety of Fluocinolone Acetonide Implant in Diabetic Macular Edema: Practical Guidelines from Reference Center
by: Lucas Sejournet, et al.
Published: (2024-09-01)